Article thumbnail

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

By Maurizio Belfiglio, Caterina Fanizza, Nicola Tinari, Corrado Ficorella, Stefano Iacobelli and Clara Natoli
Topics: Original Paper
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3258394
Provided by: PubMed Central

Suggested articles

Citations

  1. (2010). Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21(1):7–12. doi:10.1093/annonc/mdp523 228 J Cancer Res Clin Oncol (2012) 138:221–229 123Sorlie
  2. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
  3. (2008). Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/ HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.